epithelial ovarian cancer
-
August 7, 2020
Clinical Challenges: Platinum-Resistant Ovarian Cancer Bookmark
George Lundberg, MDArticle from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes:
Chemotherapy in the form of a single drug (as opposed to a combination of drugs) remains the best treatment for relapsed, platinum-resistant, serous, epithelial ovarian cancer. However, clinical trials are exploring new targeted therapy and immunotherapy options for this disease.
Go to full article published by MedPage Today.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
May 2, 2020
FDA Approves Niraparib for First-Line Maintenance of Advanced Ovarian Cancer Bookmark
George Lundberg, MDPress release from the U.S. Food and Drug Administration (FDA) curated by Editor in Chief George Lundberg, MD, who notes:
This FDA announcement is a welcome one for patients afflicted by epithelial ovarian cancer that has spread.
Go to full article published by the FDA.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.